---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-042395"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:24:35.367412+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients

## Summary
- No valve-related mortality and no moderate/severe paravalvular leak at 30 days.
- Mean gradient 8.2 mmHg; effective orifice area 2.2 cm², reflecting single-digit gradients.
- 97% freedom from moderate/severe prosthesis-patient mismatch vs 11-35% in SMART Trial.
- Technical success rate 100% in the last 50 consecutive patient implants.

## SEC filing metadata
- accession: 0001140361-25-042395
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/0001140361-25-042395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125042395/ef20059387_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-042395
- JSON: https://secwatch.observer/filing/0001140361-25-042395.json
- Plain text: https://secwatch.observer/filing/0001140361-25-042395.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.